Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Bayer Cipro

Executive Summary

Bayer Cipro: Ciprofloxacin I.V. approved Oct. 21 for the additional indication of treatment of nosocomial pneumonia caused by Haemophilus influenzae and Klebsiella pneumoniae. Cipro solution and tablets approved for use in combination with metronidazole for complicated intra-abdominal infections caused by mixed aerobic/anaerobic pathogens on Oct. 10. Cipro was approved for bacterial prostatitis in September ("The Pink Sheet" Sept. 30, In Brief)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029071

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel